1.	Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and under Sponsor: NCI, Other Protocol IDs: CDR0000732604, COG-ANHL1131, ANHL1131, NCT01595048
2.	Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 and under at diagnosis Sponsor: NCI, Other Protocol IDs: CDR0000573996, COG-AALL0631, AALL0631, NCT00557193
3.	Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia Phase: Phase III Type: Treatment Status: Active Age: 18 and under Sponsor: NCI, Other Protocol IDs: TOTXVI, 5R01CA140729, 5F32CA141762, NCT00549848
4.	Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 1 to < 10 Sponsor: NCI, Other Protocol IDs: CDR0000683227, COG-AALL0932, AALL0932, NCT01190930
5.	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: not specified Sponsor: NCI, Other Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412
6.	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 30 Sponsor: NCI, Other Protocol IDs: CDR0000706370, COG-AALL1131, AALL1131, NCT01406756
7.	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Phase: Phase III Type: Behavioral study, Treatment Status: Active Age: 1 to under 31 Sponsor: NCI Protocol IDs: NCI-2009-00307, AALL0434, CDR0000514500, COG-AALL0434, U01CA98543, NCT00408005
8.	Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: Any age Sponsor: NCI, Other Protocol IDs: 2230.00, NCI-2010-00106, P01CA078902, FHCRC-2230.00, IR-6771, NCT00789776
9.	Improving Blood Stem Cell Collection and Transplant Procedures Phase: Phase II, Phase I Type: Treatment Status: Active Age: 3 to 79 Sponsor: NHLBI Protocol IDs: 120028, 12-H-0028, NCT01517035
10.	Phase II Study of Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancy. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 65 and under Sponsor: NCI Protocol IDs: CPMC-IRB-AAAA5571, CPMC-CAMP-016, NCI-G00-1891, NCT00008216
11.	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant For Hematologic Cancer Phase: Phase II Type: Supportive care, Treatment Status: Active Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1898.00, NCI-2010-00267, P01HL036444, P01CA078902, FHCRC-1898.00, 5788, NCT00089011
12.	HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies Phase: Phase II Type: Treatment Status: Active Age: Under 24 months Sponsor: Other Protocol IDs: INF-T2, NCT00145626
13.	Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma Phase: Phase II Type: Treatment Status: Active Age: 12 to 40 Sponsor: Other Protocol IDs: 2006-0375, NCT00866749
14.	Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 75 and under Sponsor: NCI, Other Protocol IDs: 2212.00, NCI-2009-01244, P01CA018029, U19AI096111, NCT00968630
15.	CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant Phase: Phase II Type: Treatment Status: Active Age: 0 to 26 Sponsor: Other Protocol IDs: L 10,321, NYMC 525, NCT01049854
16.	Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2 Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2010-0284, NCT01200485
17.	Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Phase: Phase II Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: Not specified Sponsor: NCI, Other Protocol IDs: 2206.00, NCI-2010-02222, P01CA018029, NCT01251575
18.	Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: UCBT01, NCT01328496
19.	Hyper CVAD Plus Ofatumumab in CD - 20 Positive Acute Lymphoblastic Leukemia (ALL) Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2010-0708, NCT01363128
20.	Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL) Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 1 to 18 Sponsor: Other Protocol IDs: TINALL, NCT01506453
21.	SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma Phase: Phase II Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 365 days to 18 years Sponsor: NCI, Other Protocol IDs: 11-001, NCT01574274
22.	Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation Phase: Phase II Type: Treatment Status: Active Age: Under 75 Sponsor: Other Protocol IDs: 12-016, NCT01596257
23.	A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy Phase: Phase II Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 1 to 30 Sponsor: Pharmaceutical / Industry Protocol IDs: 100EUSA12, NCT01643408
24.	Peripheral Blood Stem Cell Transplantation Using the CliniMACS Device Phase: Phase II Type: Treatment Status: Active Age: 22 and under Sponsor: Other Protocol IDs: CHOP 07/216, NCT01071226
25.	KIR Mismatched Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy Phase: Phase II Type: Treatment Status: Active Age: 21 and over Sponsor: Other Protocol IDs: HAPNK1, NCT01807611